1. Pieters Z, Ogunjimi B, Beutels P, Bilcke J. Cost-effectiveness analysis of herpes zoster vaccination in 50- to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, the adjuvanted subunit vaccine, and live-attenuated vaccine. Pharmacoeconomics. 2022;40(4):461–76.
2. Bilcke J, Ogunjimi B, Marais C, de Smet F, Callens M, Callaert K, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096–109.
3. Bilcke J, Marais C, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, Vancorenland S, Van Kerschaver E, Callaert K, Hens N, Van Damme P, Beutels P. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Health Technology Assessment (HTA). KCE Reports 151; 2010. https://kce.fgov.be/en/publications/all-reports/cost-utility-of-vaccination-against-chickenpox-in-children-and-against-herpes-zoster-in-elderly-in.
4. EMA. Shingrix Summary of Product Characteristics (SmPC); 2022. https://www.ema.europa.eu/documents/product-information/shingrix-epar-product-information_en.pdf
5. EMA. Zostavax Summary of Product Characteristics (SmPC); 2022. https://www.ema.europa.eu/documents/product-information/zostavax-epar-product-information_en.pdf